The global wearable injectors market was valued at USD 7.61 billion in 2022 and is projected to reach USD 20.57 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 10.5% during the forecast period 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The inconveniences like needle stick injuries and limitations of traditional syringes have encouraged the adoption of the latest wearable injectors among the population. The wearable injectors eliminate the requirement of any assistance from healthcare workers and also reduce the consumer’s expenditure on healthcare. Moreover, the wearable injectors are compact and portable and allow the patient to self-administer the drugs while conveniently doing regular tasks at home or office. All these benefits offered by wearable injectors are expected to drive the demand for wearable injectors among the population during the forecast period. Moreover, technological advancements led to the development of new and innovative drugs, which requires special drug delivery devices to efficiently administer the drugs in the patient’s body. Thus rapidly growing biopharmaceutical industry is boosting the development of new and innovative drugs that subsequently fosters the growth of the global wearable injector market across the globe.
The global wearable injector market is primarily driven by the growing prevalence of various chronic diseases such as cancer, rheumatoid arthritis, diabetes, cardiovascular diseases, and other chronic diseases coupled with technological advancements in drug delivery devices. Moreover, CVD accounted for around 32% of global deaths in 2019. The rapid growth of the biopharmaceuticals and development of various drugs that can cure chronic diseases efficiently fostered the demand for drug delivery devices across the globe.
| Report Highlights | Details |
| Market Size in 2023 | USD 7.61 Billion |
| Market Size BY 2032 | USD 20.57 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 10.5% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Type, Application, End User, Region |
| Companies Mentioned | Amgen, Becton, Dickinson and Company, Dexcom, Inc., Enable Injections, Insulet Corporation, Sensile Medical, Tandem Diabetes Care, Inc., Ypsomed, F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd |
Based on the type, the on-body segment accounted for over 56% of the market share in 2022. The on-body wearable injectors are easy to wear and comfortable for the skin. This has led to the extensive adoption of on-body injectors, thereby propelling the growth of this segment. Moreover, the rising demand for home care is expected to boost the segment’s growth in the forthcoming years.
On the other hand, the off-body is estimated to be the fastest-growing segment during the forecast period. The off-body wearable injectors eliminate certain inconveniences such as adhesive fitting on the skin, painful removal of injectors, and skin irritation. The rising investments in the development of enhanced off-body injectors are expected to drive the growth of this segment in the future.
Based on the application, the oncology segment dominated the global wearable injector market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. This is attributed to the increased prevalence of cancer among the population. The increased prevalence of various cancer such as breast cancer, lung cancer, bowel cancer, and womb cancer are the major drivers of this segment.
On the other hand, autoimmune diseases are estimated to be the most opportunistic segment during the forecast period. This can be attributed to the rising prevalence of diabetes among the population and the rising demand for wearable injectors over traditional insulin pumps. According to the World Health Organization, diabetes is the major cause of kidney failure, heart attacks, blindness, and stroke. Hence, the demand for the treatment for diabetes is expected to drive the growth of this segment.
Based on the end user, the homecare segment accounted for over 41% of the market share in 2022. The increased awareness regarding wearable injectors and increasing preferences for self-injecting of drugs. Moreover, the reduction in the costs of healthcare associated with the homecare segment and the elimination of any assistance for the administration of drugs using wearable injectors are the major drivers of this segment.
Based on region, North America dominated the global wearable injector market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. This is attributed to the increased number of people suffering from various chronic diseases. According to a study, around 60% of the US population is suffering from at least one chronic disease. Moreover, the development of various innovative drugs that can effectively treat chronic diseases is fueling the demand for the wearable injector market. Moreover, the rising popularity of personalized medicines may impact the market positively in the forthcoming years.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. Asia Pacific is home to several top biopharmaceutical manufacturers. The nations like India, China, and South Korea are expected to present lucrative opportunities to the market players in the upcoming future. Moreover, the rising old-age population in the region is expected to drive the demand for wearable injectors. Geriatric people are more prone to various chronic diseases and are expected to foster market growth in the foreseeable future. According to the WHO, by 2050, around 80% of the geriatric population will be living in low and middle-income economies.
Key Companies & Market Share Insights
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.
In April 2021, Medtronic introduced a wearable injector that can be worn by patients for 7 days for the treatment of diabetes.
The various developmental strategies like product launches, acquisitions, and mergers foster market growth and offer lucrative growth opportunities to the market players.
Segments Covered in the Report
By Type
By Application
By End User
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
